Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukemia: A multi-center phase II expansion study

View Full Paper
Ask AI
Bookmark
Share

Authors

KDK. DanielsLWLei WangTWTamara Westover

Discussion

Loading...

Member takes

Overview

Phase II study demonstrates complete response in pediatric AML with venetoclax-cytarabine, indicating treatment potential.

Key Points

  • Complete response achieved in 62.5% of pediatric patients treated with venetoclax and cytarabine.
  • High-dose cytarabine-based therapy showed a 50% reduction in peripheral blast count correlating to CR.
  • Multicenter Phase I/II trial assessed venetoclax alongside classic chemotherapy for relapsed AML.
  • Study highlights treatment effectiveness, suggesting further investigations for pediatric acute myeloid leukemia.

Cite This Study

Daniels et al. (2025) studied this question.

synapsesocial.com/papers/69362f3a4fa91c937236d3ffhttps://doi.org/10.1182/blood-2025-649
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Trial in progress: A pilot study of venetoclax to AUGMENT epigenetic modification and chemotherapy in pediatric and young adult patients with relapsed and refractory Acute Myeloid Leukemia2025 · 1 citations
  2. 2Venetoclax and azacytidine in childhood primary advanced myelodysplastic syndromes, refractory/relapsed Acute Myeloid Leukemia and therapy-related myeloid diseases2025
  3. 3ITCC-101/APAL2020D: A randomized Phase 3 trial of fludarabine/cytarabine/gemtuzumab ozogamycin with or without venetoclax in children with relapsed Acute Myeloid Leukemia2025 · 1 citations
  4. 4Safety and efficacy of venetoclax plus CAG (cytarabine, aclarubicin, G-CSF) regimen in patients with relapsed or refractory Acute Myeloid Leukemia: A prospective single-arm phase II study2025
  5. 5Reduced intensive chemotherapy combined with venetoclax in adult patients with Acute Myeloid Leukemia: A retrospective single-center analysis2025